This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

BeneFIX (nonacog alfa) Prescribing Information for Great Britain click here. BeneFIX (nonacog alfa) Prescribing Information for Northern Ireland click here.
​​​​​​​
Adverse event reporting can be found at the bottom of this page.    

​​​​​​​BeneFIX® (nonacog alfa) is recombinant coagulation factor IX indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). BeneFIX® can be used for all age groups.1  

Administration and storage  

BeneFIX® is administered by intravenous infusion after reconstitution with sterile 0.234% w/v sodium chloride solution. The reconstituted product has demonstrated in-use chemical and physical stability for 3 hours at temperatures up to 25°C.

Reconstitution  

BeneFIX® can be reconstituted and administered using the R2 device.    

We’ve created the ‘BeneFIX R2 infusion mat’ as a support material for your patients. It provides a detailed and visual step-by-step guide on how to use the device.    

​​​​​​​Request the infusion mat, and any other patient and HCP materials, through the Contact Us page, linked on the right hand side. 
​​​​​​​

How to store BeneFIX®    

  • Store below 30°C.1  
  • Do not freeze.1  
  • BeneFIX® has a shelf life of 2 years.1  ​​​​​​​​​​​​​​

After reconstitution:

  • ​​​​​​​The reconstituted product does not contain a preservative and should be used immediately, but no longer than 3 hours after reconstitution.  
  • Chemical and physical in-use stability has been demonstrated for 3 hours at temperatures up to 25°C.1    

Explore More

Recommended dosing schedules1  

No two days are the same. No two patients are the same. BeneFIX® offers frequent, flexible dosing so your patients are covered for everyday life.1,2  

Find out more

Monitoring

Learn about monitoring BeneFIX® in your patients. 

Find out more

Contact us

Contact a member of the Pfizer haemophilia team.  

Contact us

** This is an optional area where footnotes can live.


References
  1. BeneFIX® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.
  2. Shapiro AD et al. Haemophilia 2005;11:571–582.    
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
​​​​​​​Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

PP-BEN-GBR-0488. September 2021.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No